Rationale Cannabidiol (CBD) products lacking regulatory approval are being used to self-
treat a myriad of conditions and for their unsubstantiated health benefits. The scientific …

Background Cannabis use is common, especially among young people, and is associated
with risks for various health harms. Some jurisdictions have recently moved to …

Background Public and medical interest in cannabidiol (CBD) has been rising, and CBD is
now available from various sources. Research into the effects of low-dose CBD on outcomes …

Objective: Despite the staggering consequences of the opioid epidemic, limited nonopioid
medication options have been developed to treat this medical and public health crisis. This …

Cannabidiol (CBD) oils are low tetrahydrocannabinol products derived from Cannabis sativa
that have become very popular over the past few years. Patients report relief for a variety of …

Background A substantial and unmet clinical need exists for pharmacological treatment of
cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which …

Abstract Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the most represented
phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different …

The laws governing cannabis are evolving worldwide and associated with changing
patterns of use. The main psychoactive drug in cannabis is Δ 9-tetrahydrocannabinol (THC) …

Considering data from in vitro and in vivo studies, cannabidiol (CBD) seems to be a
promising candidate for the treatment of both somatic and psychiatric disorders. The aim of …

Rigorous, controlled evidence for the therapeutic efficacy of CBD is lacking for many health
conditions. Possible concerns with the use of CBD as a therapeutic include the potential for …